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Diagnostic performance of a faecal immunochemical test
for patients with low-risk symptoms of colorectal cancer
in primary care: an evaluation in the South West of England
Sarah E. R. Bailey 1, Gary A. Abel1, Alex Atkins2, Rachel Byford3, Sarah-Jane Davies4, Joe Mays4, Timothy J. McDonald5, Jon Miller4,
Catherine Neck6, John Renninson4, Paul Thomas7, Fiona M. Walter8, Sarah Warren6 and Willie Hamilton1
BACKGROUND: The faecal immunochemical test (FIT) was introduced to triage patients with low-risk symptoms of possible
colorectal cancer in English primary care in 2017, underpinned by little primary care evidence.
METHODS: All healthcare providers in the South West of England (population 4 million) participated in this evaluation. 3890
patients aged ≥50 years presenting in primary care with low-risk symptoms of colorectal cancer had a FIT from 01/06/2018 to 31/
12/2018. A threshold of 10 μg Hb/g faeces defined a positive test.
RESULTS: Six hundred and eighteen (15.9%) patients tested positive; 458 (74.1%) had an urgent referral to specialist lower
gastrointestinal (GI) services within three months. Forty-three were diagnosed with colorectal cancer within 12 months. 3272 tested
negative; 324 (9.9%) had an urgent referral within three months. Eight were diagnosed with colorectal cancer within 12 months.
Positive predictive value was 7.0% (95% CI 5.1–9.3%). Negative predictive value was 99.8% (CI 99.5–99.9%). Sensitivity was 84.3% (CI
71.4–93.0%), specificity 85.0% (CI 83.8–86.1%). The area under the ROC curve was 0.92 (CI 0.86–0.96). A threshold of 37 μg Hb/g
faeces would identify patients with an individual 3% risk of cancer.
CONCLUSIONS: FIT performs exceptionally well to triage patients with low-risk symptoms of colorectal cancer in primary care; a
higher threshold may be appropriate in the wake of the COVID-19 crisis.
British Journal of Cancer https://doi.org/10.1038/s41416-020-01221-9
BACKGROUND
There are around 1.8 million new colorectal cancer (CRC)
diagnoses worldwide each year, and almost 900,000 deaths.1
Population screening is effective in reducing mortality, with a
relative risk of CRC mortality varying between 0.67 and 0.88
depending upon the screening modality, frequency of screening
and sex.2 However, even when screening is available, most CRCs
present with symptoms. In the UK, less than 10% of CRCs are
identified by screening, with the remainder identified after
symptoms have developed.3 In many countries, symptomatic
patients present first to primary care, where the general
practitioner (GP) assesses the possibility of cancer, and
investigates or refers for specialist tests if appropriate.4 The
usual diagnostic test in secondary care is colonoscopy, with CT
imaging or capsule endoscopy occasionally used.
Requests for urgent CRC investigation have relentlessly
increased over the last decade, with a parallel increase in
colonoscopies. These doubled in the UK between 2012 and
2017.5 This rise was driven in part by referral of patients whose
symptom profile, while still representing possible cancer, was
relatively low-risk.6 These patients, often with abdominal pain or
mild anaemia, had been excluded from UK national guidance in
2005,7 but transpired to have the worst survival across the
different symptoms, often presenting as an emergency.8,9 In 2015,
the National Institute for Health and Care Excellence (NICE)
published revised guidance, NG12.10 The revised NICE recom-
mendations were explicitly based on the risk of cancer posed by
the patient’s symptoms, and used only primary care evidence to
estimate this risk. Patients having a risk of CRC of 3% or more are
recommended for an urgent suspected cancer referral, and are
usually offered colonoscopy. For risks below 3%, patients were to
be offered testing for occult blood in their faeces, with those
testing positive to be referred urgently. This recommendation was
based on a systematic review performed by NICE, finding six
studies of faecal occult blood testing mostly in secondary care,
totalling 9871 patients.10 The sensitivity and specificity for colorectal
cancer varied considerably across these studies, although the
diagnostic performance was considered sufficient in the absence
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of other tests available in primary care. An economic evaluation
supported this recommendation.10
The faecal immunochemical test (FIT) for haemoglobin mea-
sures the amount of haemoglobin in a faeces sample and
has largely replaced faecal occult blood testing. NICE guidance
issued in 2017 (DG30) recommended FIT should replace faecal
occult blood testing in primary care patients with low-risk
symptoms of CRC.11 The systematic review underpinning that
recommendation found nine studies:12 in only one was the FIT
performed in primary care, though even in that study all patients
had already been selected for urgent referral for possible CRC.13
Thus all the evidence underpinning the use of FITs in primary care
in DG30 was from the high-risk referred population; this brings a
substantial risk of spectrum bias.14
This study evaluated a FIT used by general practitioners to
triage patients with low-risk symptoms of possible CRC in the
South West of England, and estimated the diagnostic performance
of FITs in this population.
METHODS
This joint South West Cancer Alliances transformation project
provided a quantitative FIT service to primary care practices across
the South West of England (population ~4 million) from June
2018. This area includes 14 secondary care providers and 10
clinical commissioning groups (CCGs), listed in Supplementary
Material.
The FIT diagnostic service (comprising of FIT kits for patients,
patient instructions, lab processing of FIT and timely associated
reporting of results) was available to GPs to triage patients with
low-risk symptoms of CRC, as defined by NG12 and DG30.10,11
Patients meeting the following criteria were eligible for a FIT
(these criteria were derived from the 2015 NG12 for faecal occult
blood testing, current at the time of project design):
● Aged 50 years and over with unexplained abdominal pain or
weight loss
● Aged 50–60 years with change in bowel habit or iron-
deficiency anaemia
● Aged 60 years and over with anaemia, even in the absence of
iron deficiency
The laboratory service was provided by Severn Pathology in
Bristol and the Exeter Clinical Laboratory in Exeter using the HM-
JACKarc analyser. This assay has a recommended analytical range of
7–400 μg Hb/g faeces (though some values below 7 μg Hb/g faeces
were reported); results over 400 μg Hb/g faeces were recorded as
>400 μg Hb/g faeces. A threshold value of ≥10 μg Hb/g faeces
defined a ‘positive’ test, as per DG30.11 Test kit packs were delivered
to primary care practices including: the test unit, instructions for use,
a form to select the indication for the test, and a prepaid envelope
for the patient to return the completed test to the laboratory.
Test results were returned to practices electronically in Devon,
Cornwall and Avon. In Somerset, Wiltshire and Gloucestershire,
reports were initially sent by post, and later electronically.
Information about the service was publicised through local CCG
newsletters and through the local Cancer Research UK Facilitator
Team, who provided practice-level training and support. GPs were
provided with written, online, and video support for using the FIT
service, indications for the test and how to use it, and advice on
how to deal with a positive test. GPs were advised in the guidance
that if faecal haemoglobin concentration (f-Hb) was ≥10 μg Hb/g
faeces they should consider using an urgent referral for suspected
cancer under the local secondary care provider’s arrangements.
They were also advised that occult blood in the faeces can be
caused by a wide variety of benign conditions as well as CRC, and
further assessment may be appropriate to rule these out before
referring.
Data collection
All patients with a FIT analysed from 1 June 2018 to 31 December
2018 were included in this study. Data extracted from the two
laboratories included the test date, result, indication, patient year of
birth and gender. Separately, each of the 14 secondary care
providers in the region extracted data, including stage at diagnosis,
on any cancer identified from 1 June 2018 to 31 December 2019
after entry into upper or lower gastrointestinal services. This
captured cancers diagnosed by all routes, including screening and
incidental findings such as routine referral or emergency admission.
This allowed for 12 months of follow-up time for all patients, during
which missed CRC diagnoses in FIT negative patients were likely (but
not certain) to be diagnosed through other routes. Had a longer
period of follow-up been chosen, some of the CRCs diagnosed in FIT
negative patients after 12 months may not have been causing
symptoms at the time of testing. Only cancers identifiable on a
gastrointestinal (GI) pathway were identified: non-GI cancers,
referred to other cancer diagnostic pathways, were not identified.
Test results were matched against referral and diagnosis data by
each of the secondary care providers using NHS number, then
removed and replaced with a randomly allocated study number.
Year of birth was used as a secondary confirmation of correct
matching of patient records. This was done to adhere with
information governance requirements and to ensure complete-
ness of the full patient pathway. GPs were advised not to offer
multiple FITs to individual patients; where more than one test was
recorded for one patient, the earliest result was used.
Statistical analysis and power calculation
Summary statistics were used to describe the cohort, and to
estimate the performance of FIT in this population, including
sensitivity, specificity, positive predictive value (PPV), and negative
predictive value. A Chi-squared test was used to compare the
proportion of male participants, and a Mann–Whitney test to
compare the median age, between those with a result at/above
and below the threshold. A receiver-operating characteristic
curve was produced for quantitative f-Hb against CRC diagnosis.
Logistic regression was used to model the relationship between
cancer and f-Hb (treated as a continuous variable), after log-
transformation to improve the final model fit. Non-linearity in the
relationship between f-Hb and CRC was explored using fractional
polynomials, though goodness of fit was not improved by doing
so. Consequently, a linear term was retained. The probability of
being diagnosed with CRC in the next year for a given f-Hb value
was estimated from the final model, in particular identifying the
value equating to an individual cancer risk of 3%, to mirror NICE
recommendations for urgent investigation.10 Stata version 16 was
used for all analyses.15 Diagnostic test summary statistics were
estimated with the DIAGT module.16
A simulation approach was used to estimate the sample size
required to achieve 95% confidence intervals of 2.2% to 4.0%
around a cancer risk of 3% from the logistic regression. Assuming
a linear relationship between f-Hb and CRC risk suggested a
sample of 2250 would be sufficient so long as the threshold was
within the central core of the distribution of f-Hb levels. It was
estimated that 10,000 tests would be used in a year; data
were collected over seven months to meet the sample size
requirement. In practice it was comfortably exceeded, increasing
precision.
Data governance
As this project was evaluating service delivery, and not changing
routine clinical practice, ethical approval was not required. Data
sharing agreements were drawn up between all parties, and
Caldicott guardian approvals were in place to allow data sharing.
The requirement for individual NHS numbers for use within this
evaluation meets the criteria set out in section 6 of the General
Data Protection Regulation: Guidance on Lawful Processing. The
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processing of data is based upon GDPR Article 6(1)(e)—‘exercise of
official authority’ and article 9(2)(h) ‘management of health and
care services’. The enabling legislation is the NHS Act 2006 section
13E, including the duty on NHS England to ‘secure continuous
improvement in the quality of services’. The same basis supported
the secondary care providers supplying data. The study protocol is
available on the University of Exeter website at http://hdl.handle.
net/10871/122303. This manuscript was deposited as a preprint
on medrXiv.17
RESULTS
From 1 June 2018 to 31 December 2018, 3890 samples were
submitted to and analysed by the two laboratories. The median
age of tested patients was 65 years (interquartile range (IQR):
56–75) and 1644 (42.6%) were male. Criteria for investigation
were: 1617 (41.6%) aged ≥50 years with abdominal pain or weight
loss; 1194 (30.7%) aged <60 years with changes in bowel habit or
iron-deficiency anaemia; 930 (23.9%) aged >60 years and with
anaemia (in absence of iron deficiency). No criteria for investiga-
tion were recorded in 149 (3.8%).
FIT results
A f-Hb ≥10 μg Hb/g faeces (test positive) was recorded for 618
patients (15.9%). Patients above the f-Hb threshold were more
often male (46.1% males vs 42.0% females, p= 0.017) and older
(median age 71 vs 63, IQR 60 to 79, p < 0.001). Of patients above
the f-Hb threshold, the median age was 71.7 years (IQR 60.1–79.7);
288 (46.3%) were male. The median result was 36 μg Hb/g faeces
(IQR 17–149). Figure 1 shows the distribution of f-Hb in patients
above the threshold.
Referrals in patients with a FIT
Of 618 patients with f-Hb ≥10 μg Hb/g faeces, 458 (74.1%) were
referred to lower gastrointestinal (GI) services within three months
(Fig. 2). Of the remaining 160, 36 were referred up to 12 months
after FIT. Cancer outcomes for these patients are shown in Fig. 2.
Of 3272 patients with f-Hb <10 μg Hb/g faeces, 324 (9.9%) were
referred to lower GI services within three months.
Cancer outcomes
Table 1 shows the cancers identified during the year after FIT. The
positive predictive value of FIT in this low-risk symptomatic
population is 7.0% (95% CI 5.1–9.3%), and the negative predictive
value is 99.8% (CI 99.5–99.9%). The sensitivity in this population is
84.3% (CI 71.4–93.0%), and the specificity 85.0% (83.8–86.1%).
The area under the ROC curve is 0.92 (CI 0.86–0.96) (Fig. 3).
The median number of days from FIT to diagnosis of CRC in
patients testing above the f-Hb threshold was 34 (IQR 23–56).
Staging data were available for 31 of 43 patients: 6 Dukes’ A; 5
Duke’s B; 12 Dukes’ C; 8 Dukes’ D. The median number of days to
diagnosis in patients with a result below the f-Hb threshold was
57 days (IQR 37–197). Staging data were available for six of eight
patients: 1 Duke’s B; 2 Dukes’ C; 3 Dukes’ D.
Cancer risk by f-Hb
Figure 4 shows the estimated probability that an individual will be
diagnosed with CRC for a given f-Hb level, estimated from the
logistic regression model. Using this model, a f-Hb level of 37 μg
Hb/g faeces (CI 26–50) in an individual with that result
corresponds to a CRC risk of 3%. Five patients with CRC had a f-
Hb value in the range 5–9 μg Hb/g faeces.
DISCUSSION
This study reports the use of FIT for detection of CRC in a primary
care symptomatic population. The test performed very well using
the threshold value of ≥10 μg Hb/g faeces. Test sensitivity and
specificity were 84.3% and 85.0%, respectively, both notably high
figures for a primary care cancer test. Using this threshold, the
positive predictive value of f-Hb ≥10 μg Hb/g faeces was 7.0%, and
the negative predictive value 99.8%, in a population with an
overall prevalence of CRC of 1.3%. FIT also performed well
irrespective of gender or age. A f-Hb level of 37 μg Hb/g faeces
corresponded to an individual’s CRC risk of 3%.
Strengths and limitations
The strengths of this study are its size, and its setting being where
the test will be used, eliminating spectrum bias. The three
symptom groupings used by GPs to prompt FIT were estimated to
have PPVs in primary care in the range 1–3%, and the overall
prevalence of 1.3% fell within that range. These defined symptoms
match the current (September 2020) NICE guidance on when to
offer faecal testing for colorectal cancer to adults without rectal
bleeding.10 Every one of the 14 secondary care providers in the
region were recruited, increasing reliability and generalisability.
Cancer metrics in the NHS are very accurately maintained;
dedicated cancer managers ensure accurate data recording, and
secondary care provider performance on cancer metrics is
regularly published in the public domain. Furthermore, all
secondary care providers of cancer services within England are
required to use nationally defined datasets eliminating disparity in
data definitions. Despite the thorough methods, it is possible that
a small number of cancers were missed, although this is unlikely to
affect the overall interpretation of the results. Crucially, the
methods allowed the identification of CRCs in those not offered
further investigation after the FIT result was received, and a long
follow-up period of 1 year was achieved.
The age group studied, with a median age of 65 years for those
tested, is close to the median age for CRC diagnosis of 72 years,
suggesting the GPs were using the test in those genuinely
considered to have a real—but small—risk of cancer. More
women were tested, whereas CRC is slightly more common in
men. This may reflect the entry criteria, particularly with two of the
three criteria incorporating iron-deficiency anaemia, a condition
more common in women,18 or the fact that women are more likely
to seek medical intervention.19 Symptom data could not be
verified, but the overall prevalence figure suggests testing was
rarely extended into higher-risk groups. Completing the test was
patient driven; only tests which were completed and returned to
the lab were reported; it is not known how many tests were























Fig. 1 Histogram of quantitative faecal immunochemical test
results. This histogram presents the quantitative faecal immuno-
chemical test results for patients with a f-Hb over the threshold of
10 μg Hb/g faeces (618 primary care patients), with low-risk
symptoms of possible colorectal cancer.
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participating laboratories used the same FIT system; achieving
consistency across the cohort, but meaning the results are not
applicable to other systems.20
Comparison with previous literature
Three recent studies can be compared, as they examined FIT in
the symptomatic primary care population, rather than the
screening or referred populations: two of these also used a
threshold of 10 μg Hb/g faeces. Juul et al. studied 3462 Danish
primary care patients aged ≥30 years, with symptoms not meriting
urgent colonoscopy, but not defined further.21 In that study, FIT
was also recommended in patients diagnosed with irritable bowel
syndrome, lest this were a misdiagnosis. 15.6% patients tested
over the threshold, and 9.4% of these (CI 7.0–11.9%) had a CRC
diagnosed in the next 3 months. There were fewer than three
cancers identified in those below the threshold (the inexact
number reflecting Danish data protection rules). Nicholson et al.
followed up 9896 primary care patients in Oxfordshire, England,
for 6 months after FITs were ordered in primary care. The entry
criteria did not match NICE guidance DG30 or NG12, and included
rectal bleeding. The sensitivity for CRC was 90.5% (CI 84.9–96.1%),
and the positive predictive value of a positive test 10.1% (CI
8.2–12.0%).22 Chapman et al. stratified patients presenting in
primary care with any lower GI symptoms (except rectal bleeding
or a rectal mass) by f-Hb level, and anaemia in one strata.23 PPVs
were: 30.0% in the ≥150.0 μg Hb/g faeces group; 4.4% in the
10.0–149.9 μg Hb/g faeces group; 0 in the 4.0–9.9 μg Hb/g faeces
Patients with low-risk
symptoms and a FIT
N = 3890
f-Hb ≥10 μg Hb/g faeces
n = 618 (15.9%)
Lower GI referral
within 3 months
n = 458 (74.1%)
Lower GI referral
within 3 months
n = 324 (9.9%)
No lower GI referral
within 3 months
n = 160 (25.9%)
No lower GI referral
within 3 months
n = 2948 (90.1%)
Colorectal cancers
n = 33 (7.2%)
*1 diagnosed after referred to upper GI services within 3 months; 9 following delayed GP referral (>3 months after FIT)
**1 following emergency admission; 1 following screening; 1 following delayed GP referral (>3 months after FIT)
Colorectal cancers
n = 5 (1.5%)
Colorectal cancers
n = 10 (6.2%) *
Colorectal cancers
n = 3 (0.1%) **
f-Hb <10 μg Hb/g faeces
n = 3272 (84.1%)
Fig. 2 Flow diagram of referrals and diagnoses in patients with a FIT. This flow diagram shows the number of patients tested, split by test
result (over/at or under the threshold), and subsequent lower gastrointestinal referrals and colorectal cancers diagnosed.
Table 1. The number of colorectal, oesophago-gastric and pancreatic
cancers diagnosed in total, for patients with f-Hb at/above and below
the 10 μg Hb/g faeces threshold, within 12 months of FIT date.
Cancer Total ≥10 μg Hb/g faeces <10 μg Hb/g faeces
n= 618 n= 3272
Colorectal 51 43 (7.0%) 8 (0.2%)
Oesophago-gastric 9 3 (0.5%) 6 (0.2%)
Pancreatic 7 1 (0.2%) 6 (0.2%)














Fig. 3 Receiver operator characteristic (ROC) curve for the faecal
immunochemical test in the low-risk symptomatic primary care



























Faecal haemoglobin concentration (μg Hb/g faeces)
Fig. 4 Predicted probability of colorectal cancer against f-Hb,
with 95% confidence limits. The orange line shows the f-Hb level
that corresponds to a colorectal cancer risk of 3% in an individual
with that result.
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with anaemia group, 2.9% in the 4.0–9.9 μg Hb/g faeces without
anaemia group and 0.2% in the <4.0 μg Hb/g faeces group. The
PPV of 7% for results over the 10 μg Hb/g faeces threshold in the
present study is the lowest of the three that used that threshold,
which may reflect the stricter criteria for use, in particular
excluding patients with rectal bleeding, but matching current
national guidance.10 The PPV in patients with f-Hb from 4.0–9.9 μg
Hb/g faeces in our cohort was 1.7%; comparable to Chapman
et al.’s results.23 As a comparison, the sensitivity of 84.3% reported
here is higher than in the screening population of 67.0% (CI
59.0–74.0%, with thresholds of >50 μg/g24), and lower than that in
referred populations of 93.3% (CI 80.7–98.3%, thresholds of >10
μg/g).25
Clinical and research use of the results
The values reported in this study are excellent for a cancer triage
test in primary care. The performance of diagnostic tests is
generally worse as the prevalence of the target condition falls.14
In primary care, gastrointestinal complaints are common, and the
symptoms of CRC overlap both with less common cancers, such as
pancreatic or oesophago-gastric, and with common benign
conditions. With most symptoms (apart from rectal bleeding)
the likelihood of CRC is low, often in the range 1–3%.26 A large UK
primary care study showed that patients would opt for cancer
investigation even for risks as low as 1%.27 FIT has been
introduced to allow primary care investigation of such patients.
It works in classical Bayesian fashion: from a prior risk of CRC of
1.3% in the symptomatic population, a result over the 10 μg Hb/g
faeces threshold increased the risk to 7.0%, and a result below the
threshold reduced it to 0.2%, which is approximately the whole
population background risk, including those without symptoms.26
Furthermore, in five of the eight cancers with a result under the
threshold, the patient’s GP still requested urgent investigation for
possible CRC, probably because continuing symptoms allowed the
GP to ‘overrule’ the negative test. Conversely, nearly a quarter
of patients who tested over the threshold were not offered
investigation within three months, although ultimately all who
had CRC were investigated within a year. CRC incidence was
similar in those who were referred within three months and those
who were referred later; delays in the referral process should be
avoided.
Other cancers were diagnosed in participants in this study.
Sixteen oesophago-gastric or pancreatic cancers were found, only
four having a FIT result over the threshold. This suggests that GPs
should consider other intra-abdominal cancers in patients with
f-Hb < 10 μg Hb/g faeces and continuing symptoms, even though
FIT is intended for the detection of colorectal cancers as Hb is
immunologically degraded in the small intestine.
While the PPV at or above the current threshold of 10 μg Hb/g
faeces is 7%, the risk of having CRC for an individual with f-Hb of
exactly this value is 1% or lower (Fig. 4). Given this risk is lower
than the 3% chosen to underpin the NICE NG12 recommendations
for urgent cancer investigation,10 there may be scope to raise the
threshold at which urgent definitive investigations are under-
taken. f-Hb of 37 μg Hb/g faeces (CI 26–50) would identify those
with a personal 3% risk of cancer, though the large uncertainty on
this estimate may warrant the use of a lower value until more data
are available to reduce this uncertainty. Such a change may be
appropriate while endoscopy resources are severely curtailed by
COVID-19 precautions, with ‘safety netting’ by GP review for those
with f-Hb levels between 10 and 36 μg Hb/g faeces.28 In the long
term, however, the UK’s aspiration is for improvements in cancer
diagnosis to increase the proportion of cancer patients diagnosed
at stage I or II to 75% by 2028 (from a pre-COVID ~53%).29 If CRC
improvements are to contribute to this target, it may be that the
threshold should be retained at 10 μg Hb/g faeces, or even
lowered further, though not below the level where the test is
considered reliable, currently 7 μg Hb/g faeces.
Several research needs arise from this study. The first is a health-
economic analysis, examining the choice of f-Hb threshold from that
perspective. Second, it may be possible to combine data on
symptoms, other lab tests, and demographics with f-Hb to increase
the predictive power of FIT. A third strand of research—not directly
related to this study, but overlapping—considers whether FIT can be
used to triage the high-risk population. Such studies are underway;
in Scotland, patients reporting rectal bleeding (considered a ‘red
flag’ symptom) in primary care with a f-Hb <10 μg Hb/g faeces were
unlikely to be harbouring CRC or other serious bowel disease;30
similar results were observed in Sweden.31 Those will complement
the study reported here, and establish the final place for FIT in
colorectal cancer triage.
CONCLUSION
FIT in the low-risk primary care population performs well. False-
negatives are few in number, and many of those with a false-
negative test appear to receive timely investigation despite f-Hb
below the 10 μg Hb/g faeces threshold. The false-positive rate is
93%, meaning 13 patients with f-Hb over 10 μg Hb/g faeces have to
undergo colonoscopy to identify one CRC. This is a major diagnostic
advance; low-risk patients were previously either not investigated,
and had more emergency admissions and worst survival,8,9 or were
referred for colonoscopy. The background rate of cancer of 1.3% in
this population meant 77 patients had to be offered colonoscopy to
identify one cancer, potentially swamping endoscopy services, and
putting patients at a small risk of complications. Clinically, therefore,
FIT works, although health-economic aspects are as yet uncertain.
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